Offers Claimed: 146
Downloaded Today: 195
USARx offers the following ways to purchase this medication. Choose the Best option for you!
Yes100% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$42 – $417
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your myrbetriq prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about mirabegron. Some of the dosage forms listed on this page may not apply to the brand name Myrbetriq.In Summary
Common side effects of Myrbetriq include: hypertension. Other side effects include: urinary tract infection. See below for a comprehensive list of adverse effects.For the Consumer
Applies to mirabegron: oral tablet extended release
Along with its needed effects, mirabegron (the active ingredient contained in Myrbetriq) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking mirabegron:
Incidence not known
Some side effects of mirabegron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
For Healthcare Professionals
Applies to mirabegron: oral tablet extended releaseGeneral
The more commonly reported adverse reactions have included hypertension, nasopharyngitis, urinary tract infection, and headache.Cardiovascular
Very common (10% or more): Hypertension (up to 11.3%)
Common (1% to 10%): Tachycardia
Uncommon (0.1% to 1%): Atrial fibrillation, palpitations, worsening of preexisting hypertension
In 2 randomized controlled studies, dose-related increases in supine blood pressure occurred. At the maximum recommended dose of 50 mg per day, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg.Dermatologic
Uncommon (0.1% to 1%): Urticaria, rash, pruritus, lip edema, macular rash, papular rash
Rare (less than 0.1%): Leukocytoclastic vasculitis, purpura, angioedema
Angioedema of the face, lips, tongue, and/or larynx has been reported. In some case, this occurred after the first dose or after multiple doses.Gastrointestinal
Common (1% to 10%): Nausea, constipation, diarrhea, abdominal pain
Uncommon (0.1% to 1%): Dyspepsia, gastritis, abdominal distension
Rare (less than 0.1%): Lip edemaGenitourinary
Common (1% to 10%): Urinary tract infection
Uncommon (0.1% to 1%): Nephrolithiasis, bladder pain, cystitis, vaginal infection, vulvovaginal pruritus
Postmarketing reports: Urinary retention
Urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonists for the treatment of overactive bladder. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patient taking this drug.Musculoskeletal
Common (1% to 10%): Arthralgia
Uncommon (0.1% to 1%): Joint swellingNervous system
Common (1% to 10%): Headache, fatigue, dizzinessOcular
Uncommon (0.1% to 1%): Glaucoma, blurred vision, dry eyes
Rare (less than 0.1%): Eyelid edemaOncologic
Rare (less than 0.1%): Prostate cancerRespiratory
Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitisHepatic
Uncommon (0.1% to 1%): Increased ALT, AST, and GGTPsychiatric
The majority of patients reporting confusion, hallucinations, insomnia, and anxiety had preexisting conditions or were using concomitant medications that may have contributed to these events.
Postmarketing reports: Confusion, hallucinations, insomnia, anxiety
May 9, 2021
March 31, 2021
March 29, 2021
March 27, 2021
January 25, 2021
February 23, 2021